Literature DB >> 10453891

Development of nonspecific interstitial pneumonitis associated with long-term treatment of primary pulmonary hypertension with prostacyclin.

S Kesten1, J Dainauskas, V McLaughlin, S Rich.   

Abstract

A young woman with primary pulmonary hypertension presented with interstitial lung disease approximately 5 years after successful treatment with IV prostacyclin. The pathology was consistent with nonspecific interstitial pneumonitis and was unresponsive to steroids and immunosuppressive medications. We speculate that further cases of this syndrome may be reported as more patients are living beyond 5 years with prostacyclin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10453891     DOI: 10.1378/chest.116.2.566

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

1.  Flow cytometric characterization of the saphenous veins endothelial cells in patients with chronic venous disease and in patients undergoing bypass surgery: an exploratory study.

Authors:  Cláudia Torres; Rui Machado; Margarida Lima
Journal:  Heart Vessels       Date:  2019-06-21       Impact factor: 2.037

2.  Iloprost attenuates hyperoxia-mediated impairment of lung development in newborn mice.

Authors:  Nelida Olave; Charitharth Vivek Lal; Brian Halloran; Vineet Bhandari; Namasivayam Ambalavanan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-06-28       Impact factor: 5.464

3.  Epoprostenol-associated pneumonitis: diagnostic use of a T-cell proliferation assay.

Authors:  Kristina T Kudelko; Kari Nadeau; Ann N Leung; Juliana Liu; François Haddad; Roham T Zamanian; Vinicio De Jesus Perez
Journal:  J Heart Lung Transplant       Date:  2010-06-08       Impact factor: 10.247

4.  Pulmonary vasodilators can lead to various complications in pulmonary "arterial" hypertension associated with congenital heart disease.

Authors:  Ayako Chida-Nagai; Koichi Sagawa; Takao Tsujioka; Takanori Fujimoto; Kota Taniguchi; Osamu Sasaki; Gaku Izumi; Hirokuni Yamazawa; Naoki Masaki; Atsushi Manabe; Atsuhito Takeda
Journal:  Heart Vessels       Date:  2020-04-13       Impact factor: 2.037

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.